Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVG-2089 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07027111Phase 2Terminated
- Sponsor
- Biohaven Ltd.
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Antibody Fragments, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NVG-2089 in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Biohaven Ltd.. Started Apr 2025; status: terminated.
02
Drugs
NVG-2089
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT07027111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07027111.